Lv5
1088 积分 2023-12-07 加入
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
12天前
已完结
New perspectives for targeting therapy in ALK-positive human cancers
16天前
已完结
Prostate cancer
1个月前
已完结
Prostate cancer
1个月前
已完结
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial
1个月前
已完结
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
3个月前
已完结
An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer
3个月前
已完结
Strategies for successful dose optimization in oncology drug development: a practical guide
3个月前
已完结
Top advances of the year: Bladder cancer
4个月前
已完结
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers
4个月前
已完结
皖公网安备34019202002308
